Clinical Trial Update: Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the combination of tislelizumab and disitamab-vedotin as neoadjuvant therapy for HER2-positive high-risk upper tract urothelial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Neoadjuvant Immunotherapy | Phase 2 | Status: RECRUITING